Brain Energy for Amyloid Transformation in Alzheimer's Disease Study
{ "Brain Energy for Amyloid Transformation in Alzheimer's Disease Study", "This study, called BEAT-AD, is looking at how different diets affect adults with mild cognitive impairment. You would be randomly assigned to follow either a Modified Mediterranean-Ketogenic Diet (low carbohydrate/high fat) or an American Heart Association Diet (low fat/high carbohydrate) for 16 weeks. Researchers want to see if these diets change your thinking abilities, blood flow in your brain, and levels of certain proteins and hormones. The main goal is to measure a specific protein in your spinal fluid (Cerebrospinal Fluid or CSF Abeta42) after 16 weeks to see the diet's impact. The study is for people aged 55 to 85 with mild cognitive impairment and a study partner. The current status of the study is unclear.", "design": "This interventional study plans to enroll 120 participants who will be randomly assigned to one of two diet groups.", "commitments": "You would follow a specific diet for 16 weeks, with clinic visits and phone sessions occurring at baseline and throughout the 24-week study period.", "compensation": "Not stated in the trial record.", "follow_up": "There will be a follow-up assessment 8 weeks after the 16-week diet completion, making the total study duration 24 weeks.", }
- Study design
- Not specified.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Not specified.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Brain Energy for Amyloid Transformation in Alzheimer's Disease Study
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Suzanne Craft, PhD · PRINCIPAL_INVESTIGATOR · Wake Forest University Health Sciences
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Cerebrospinal Fluid Abeta42baseline
Aβ42 is a a key Alzheimer's disease biomarker that reflects pathological aggregation of amyloid in the brain.
- Cerebrospinal Fluid Abeta42week 16
Aβ42 is a a key Alzheimer's disease biomarker that reflects pathological aggregation of amyloid in the brain.